Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases
Megestrol is an effective palliative treatment for endometrial carcinoma. Some persons with progestin-responsive cancer continue on hormonal therapy for months or even years. In persons who respond to megestrol, long term use can cause weight gain and other side effects via activity of the drug at t...
Saved in:
Main Authors: | William L. Read (Author), Sumita Trivedi (Author), Felicia Williams (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2017-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of megestrol for the treatment of patients with atypical endometrial hyperplasia or endometrial endometrioid adenocarcinoma (Stage IA, well differentiated)
by: Setareh Akhavan, et al.
Published: (2021) -
Norethindrone Acetate in the Medical Management of Adenomyosis
by: Siddhi Mankame, et al.
Published: (2012) -
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
by: Xin Zhao, et al.
Published: (2022) -
Medical management of recurrent endometrioma with long-term norethindrone acetate
by: Muneyyirci-Delale O, et al.
Published: (2012) -
Megestrol acetate for cachexia-anorexia syndrome. A systematic review
by: Vicente Ruiz‐García, et al.
Published: (2018)